Kornimate/medical-research-clean huggingface dataset:
efficacy of a phone application on treatment adherence in asthmatic patients in upper egypt

Conditions: Bronchial Asthma; Adherence, Medication

Summary: asthma adherence is mandatory for disease control

asthma is a chronic and common disease of the airways that affects more than 339 million people globally \[1\]. according to who estimates, there were 417,918 deaths due to asthma at the global level and 24.8 million disability-adjusted life years (dalys) attributable to asthma \[2, 3\]. there is much evidence that self-care by patients with asthma has beneficial outcomes, including reduced hospital stays, reduced symptoms, and general compliance with treatments \[4-6\]. one of the approaches for promoting self-care skills in patients with asthma is to provide self-care services (i.e., providing basic information about the nature of asthma, avoiding exposure to allergens and triggers, treating with drugs, providing alerts and reminders to patients, and how to use the therapeutic tools \[7\]) through information technology tools (e.g. the internet, mobile phones, and computer software). given the increasing worldwide use of smartphones, mobile health (mhealth) technologies can work as promising tools to improve self-care in patients with asthma by providing support services such as communication information, providing learning materials, and sending reminders for behavior change \[8, 9\]. mhealth, as a component of electronic health, is related to the use of mobile phones and other wireless technologies to improve the provision of health-related services. moreover, ease of use, portability, and ubiquity in all regions are the potential benefits of mhealth tools for the prevention, diagnosis, treatment, and care of diseases also increasing access to health services and reducing the costs incurred \[10\]. this study aims to evaluate the role of a mobile application in reminding the patient to take his treatment and its reflection on asthma control and quality of life.

Eligibility criteria:
inclusion criteria: doctor-diagnosed asthma. on at least global initiative for asthma (gina) step 3 which means they will be on regular inhaled steroids. no change in regular asthma treatment in the last 1 month sufficient english-language ability to understand the text in mobile phone-delivered interventions the education level required will be at least a high school diploma. exclusion criteria: gina step 5 asthma (complex issues, too unstable). recent changes to asthma treatment within the last month another chronic health condition (eg diabetes, congenital heart disease, cystic fibrosis) patients without mobile device skills
study of alxn1840 versus standard of care in pediatric participants with wilson disease

Conditions: Wilson Disease

Summary: this study is being conducted to evaluate the efficacy, safety, pharmacokinetics (pk), and pharmacodynamics of alxn1840 versus standard of care in pediatric participants with wilson disease (wd).

participants who complete the 48 weeks of treatment in period 1 will have the option to receive alxn1840 for 24 weeks in period 2 (open-label extension). safety will be monitored throughout the study.

Eligibility criteria:
key inclusion criteria: 1. diagnosis of wilson disease by leipzig score ≥ 4. 2. adequate venous access to allow collection of required blood samples. 3. able to swallow intact alxn1840 tablets or mini-tablets. 4. willing to avoid intake of foods and drinks with high contents of copper. 5. willing and able to follow protocol-specified contraception requirements. key exclusion criteria: 1. decompensated hepatic cirrhosis or meld score \> 13 (ages 12 to \ 13 (ages 3 to \< 12). 2. modified nazer score \> 7. 3. clinically significant gastrointestinal bleed within past 3 months. 4. alanine aminotransferase (alt) \> 2 × upper limit of normal (uln) for participants treated for \> 28 days with wd therapy or alt \> 5 × uln for treatment-naïve participants or participants who have been treated for ≤ 28 days. 5. marked neurological disease requiring either nasogastric feeding tube or intensive inpatient medical care. 6. hemoglobin less than lower limit of the reference range for age and sex. 7. history of seizure activity within 6 months prior to informed consent/assent. 8. participants in renal failure, defined as in end-stage renal disease on dialysis (chronic kidney disease stage 5) or estimated glomerular filtration rate \< 30 milliliters/minute/1.73 meter squared.

Keywords: wilson disease pediatric
comparison of exercise and massage in fibromyalgia

Conditions: Fibromyalgia

Summary: the present study was designed to analyse and compare the effects of pilates exercises and connective tissue massage in terms of pain intensity, pain pressure threshold and tolerance, anxiety, progress, and health related quality of life in females with fibromyalgia (fm)

treatment of fm is difficult. conventional treatments do not appear to be managing the problem effectively and this has led to other forms of treatment. the aim of treating fm is to decrease pain and increase function by means of a multimodal therapeutic strategy, which, in most cases, includes pharmacological and non-pharmacological interventions. in the literature on non-pharmacological treatment approaches for fm, different managements are described, such as exercise, electrotherapy, patient education, self-management programmes, massage techniques, cryotherapy, and acupuncture. there are a number of reasons why patients choose these complementary and alternative medicine approaches, including dissatisfaction with conventional treatments or concerns over the toxicity of drugs. however, there is no consensus about which treatment approach is the best.the current randomised controlled trial was undertaken as a first pilot study to assess and compare the effectiveness of pilates exercises, an active-group therapy, and connective tissue massage, a passive-personalised therapy, in the management of fm in females.

Eligibility criteria:
inclusion criteria: * being female * being over 25 years old * meeting the criteria for fm as defined by the american college of rheumatology * having pain in the neck and shoulder region * never having been treated for fm. exclusion criteria: * infection * fever or an increased tendency to bleed * severe physical impairment * inflammatory diseases * cardiopulmonary disorders * uncontrolled endocrine disorders * allergic disorders * pregnancy * malignancy * severe psychiatric illnesses * factors known to affect autonomic function * medication usage

Keywords: pilates exercises connective tissue massage
evaluation of chemo-mechanical caries removal materials in caries removal

Conditions: Dental Caries

Summary: • the evolution of conservative dentistry that adopts the preservation of tooth structure and affected dentin that can remineralize and save the pulp from exposure, in addition to pain and fear that companies' traditional caries removal methods had led to the development of chemomechanical caries removal materials (cmcr). the old generations of cmcr agents were naocl-based materials which have disadvantages such as odor taste, unpleasant smell, high cost, limited shelf life, and time consumption. • all of the reasons described led to a new generation of cmcr materials depending on enzymes such as papain. brix3000 and papacarie duo are papain-based materials with promising effects in caries removal and fewer disadvantages. selecti-solve is a dental gel whose active ingredient is papain enzyme, it removes dental caries without the need for anesthesia and is selective for the infected dentin layer only which avoids the unnecessary loss of dentin, enamel breaking, and pulp exposure. this study aims to evaluate the efficacy of papain-based materials compared to old naocl-based materials in reducing the disadvantages of cmcr agents.

in previous literature, there has not been any study that compared the whole group of chemo-mechanical caries removal materials with such a unique collection of papain-based cmcr agents. papain-based agents could be promising materials in the evolution of atraumatic restorative treatment (art) and chemomechanical caries removal methods that support conservative dentistry and the conservation of tooth structure and pulp vitality. brix3000 has ebe technology (encapsulating buffer emulsion) that claims to elevate the efficiency of papain enzyme and permits the use of a higher concentration of papain 3,000 u/mg in the whole material (10%). papacarie duo has a unique combination of the main component of papain enzyme 6,000 u/mg and a small percentage of chloramine t that claims to increase efficiency and reduce the side effect of chloramine-based cmcr materials. selecti-solve is a new material that consists of papain as the main product and has promising effects in chemo-mechanical caries removal methods.

Eligibility criteria:
inclusion criteria: * wide carious lesion (class 1 black) on molars at the middle third of dentine confirmed with a periapical x-ray * no pulp involvement is assured with a periapical radiograph. * good oral hygiene * cooperated patient. * no oral diseases. exclusion criteria: * pulp exposure or bleeding during excavation. * pregnancy * systematic diseases * gingival and periodontal involvement. * lack of patient cooperation.

Keywords: chemo-mechanical caries removal papain-based agents minimum invasive dentistry conservative dentistry dental fear tooth decay
vardenafil in greenlight(tm) laser surgery of benign prostate hypertrophy

Conditions: Prostatic Hypertrophy, Benign

Summary: the greenlight laser has an absorption maximum which is exactly the same as for hemoglobin. in the presence of hemoglobin, its application causes vaporization of the tissue and this effect depends on the concentration of hemoglobin in the respective tissue. therefore, increase of blood-flow in the tissue (here: prostate gland) should exert better efficacy of the laser application and consequently shortening of the required duration of laser application.


Eligibility criteria:
inclusion criteria: * men with benign prostate hypertrophy requiring surgical treatment * age up to 80 years * documented, dated, written informed consent * anesthesiologists agreement with swallowing 1 tablet one hour prior surgery exclusion criteria: * any unstable medical, psychiatric, or substance abuse disorder * history of previous prostatectomy * patients suspect of prostate cancer * hereditary degenerative retinal disorder * history of previous non-arteric anterior ischemic optic neuropathy (naion) episode or unilateral vision impairment * any cardiovascular condition * history of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months * uncontrolled atrial fibrillation/flutter at screening * severe chronic or acute liver disease * chronic hematological disease which may lead to priapism * bleeding disorder * significant active peptic ulceration * resting hypotension * history of positive test for hepatitis b surface antigen or hepatitis c * symptomatic postural hypotension within 6 months of visit 1 * patients who subjectively or in the opinion of the investigator did not tolerate the initial dose of study medication well * subjects who are taking nitrates or nitric oxide donors * subjects who are taking androgens or anti-androgens * subjects who are taking potent inhibitors of cytochrome p4503a4 * subjects who have received any investigational drug within 30 days of visit 1 * using of alpha-blockers during two days prior to first dosing of study medication and after ablation of prostate * use of inhibitors of 5-alpha reductase after ablation of prostate * subjects with serum creatinine clearance \<30.0 ml/min * elevation of aspartate aminotransferase (ast) and/or alanine aminotransferase (alt) \>3 times the upper limit of normal * subjects with known hypersensitivity to vardenafil * subjects who are illiterate or unable to understand subject diaries * subjects who would be non-compliant with the study visit schedule
5-year safety study of pimecrolimus cream 1% in infants 3 - 12 months of age with mild to moderate atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical corticosteroids (tcs).


Eligibility criteria:
inclusion criteria: * aged 3 to \< 12 months * diagnosis of ad fulfilling the diagnostic criteria of seymour * ad affecting at least 5% total body surface area * investigator's global assessment (iga) score of 2 or 3, corresponding to mild-to-moderate disease at baseline * informed consent exclusion criteria: * phototherapy, systemic therapy (e.g., immunosuppressants, cytostatics), systemic corticosteroids within 4 weeks * topical tacrolimus or pimecrolimus within 2 weeks * topical therapy (e.g., tar, topical corticosteroids) within 3 days * immunocompromised (e.g., lymphoma, aids, wiskott-aldrich syndrome) or have a history of malignant disease * active acute viral skin infection (e.g. herpes simplex, herpes zoster, chicken pox), and/or clinically infected ad * failure to thrive (e.g., weight or height/length below the 5th percentile) or developmental abnormalities such as head circumference less than 5th and more than 95th percentile * known hypersensitivity to any ingredient of pimecrolimus cream 1% or topical corticosteroids * clinical conditions other than ad that according to investigator can interfere with the evaluation

Keywords: atopic dermatitis, children, infants, pimecrolimus
the effect of adaptive servo ventilation and oxygen therapy in central sleep apnea patients

Conditions: Chronic Heart Failure; Sleep Apnea

Summary: the aim of this study is to compare the effects of adaptive servo ventilation (bipap® auto sv advanced) and oxygen therapy in chronic heart failure patients complicated with central sleep apnea.

central sleep apnea(csa) is associated with chronic heart failure(chf). at present, both of nocturnal oxygen therapy and adaptive servo ventilation(asv) are recognized as effective modalities. however,in fact, majority of chf patients are complicated not only with csa but with obstructive sleep apnea(osa). recently, philips developed bipap® auto sv advanced for such patients. it has auto-cpap function as the modality of osas, in addition to asv function. the present study is prospective randomised study to compare the effects of nocturnal oxygen therapy and bipap® auto sv advanced.

Eligibility criteria:
inclusion criteria: * left ventricular ejection fraction\<50% confirmed by echocardiography * apnea hypopnea index(ahi)\>=20 confirmed by overnight polysomnography * more than 15% of ahi is due to csa exclusion criteria: * changes of cardioactive drug prescriptions within 6 weeks * admission due to cardiovascular events within 6 weeks * ever used cpap or asv for sleep apnea * ever used nocturnal oxgen therapy * subjects with acute exacerbation of chronic heart failure * operation for upper airway within 90 days * renal dialysis * history of stroke with neurological deficit

Keywords: chronic heart failure central sleep apnea obstructive sleep apnea adaptive servo ventilation
long term effects of tyrosine kinase inhibitor therapy on ovarian reserve and fertility in patients with chronic myeloid leukemia or gastrointestinal stromal tumor

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Gastrointestinal Stromal Tumor; Premenopausal

Summary: this pilot research trial studies the long term effects of tyrosine kinase inhibitor therapy on ovarian reserve and fertility in patients with chronic myeloid leukemia or gastrointestinal stromal tumor. studying ovary imaging, ovarian reserve markers, and hormone levels from patients receiving tyrosine kinase inhibitor therapy may help doctors learn more about the effects of tyrosine kinase inhibitor therapy on ovarian function and fertility.

primary objectives: i. to collect preliminary information to help design a study to look at longitudinal changes in markers of ovarian reserve and menstruation in premenopausal women undergoing tyrosine kinase inhibitors (tki) therapy. secondary objectives: i. evaluate ovarian response to controlled ovarian hyperstimulation in patients who elect to undergo in vitro fertilization (ivf) for fertility preservation. outline: patients undergo transvaginal ultrasound for antral follicles analysis and collection of serum for ovarian reserve markers and hormonal analysis before tki therapy and at 12, 24, and 48 weeks.

Eligibility criteria:
inclusion criteria: * diagnosed with chronic myeloid leukemia (cml), gastrointestinal stromal tumor (gist), non metastatic cancer where tki is the first line agent * premenopausal (has had menses at any time in the preceding 12 consecutive months) * has not undergone a hysterectomy or bilateral oophorectomy * willing to use non-hormonal (ie: barrier method or abstinence) as form of contraception during the one year of study exclusion criteria: * patients who have had chemotherapy or radiotherapy in the past * patients may not be receiving any other investigational agents * patients must not be pregnant or nursing * other medical conditions or treatments that affect hormonal levels (potentially confounding interpretation of results) * patients with ongoing hormonal contraception or unwilling or unable to discontinue will not eligible
targeting neuroinflammation as a contributing pathology in alzheimer's disease dementia

Conditions: Alzheimer Disease

Summary: this study is being done to research the usefulness of pet/ct imaging for measuring brain inflammation and its relation to alzheimer's disease. additionally, researchers as looking to learn more about the side effects of a new radioactive tracer (radiotracer) c-11 er176.

alzheimer's disease (ad) dementia is a devastating illness with no cure. treatments targeting known pathologic hallmarks of ad, such as amyloid-beta (ab), in symptomatic individuals have proved largely fruitless so other potential disease targets warrant exploration. neuroinflammation has interesting possible associations with ad dementia and may contribute to ad dementia in different ways among different individuals. previous pet neuroinflammation data are not entirely consistent and new methods of pet imaging and studies with larger cohorts are needed to further investigate the role of neuroinflammation in ad dementia and the utility of pet as a biomarker. this project seeks to test new pet neuroinflammation imaging methods in unimpaired and ad dementia individuals with biomarker-identified brain pathology to help address these gaps in knowledge in the field.

Eligibility criteria:
inclusion criteria: * males or females 60 years of age or older. * meet the requirements for one of the four groups (cu a-, cu a+, mci a+, ad a+). * undergoing neurologic evaluation procedures with cognitive testing in the mcsa or - adrc for a minimum of about 3 years. * all participants must have had an amyloid pib pet scan and mri brain scan within the previous 6 months. * capacity to sign consent or have a legally authorized representative to sign the consent. exclusion criteria: * participants unable to lie down without moving for 20 minutes. * women who are pregnant or cannot stop breast feeding for 24 hours. * actively taking daily anti-inflammatory medications (nsaids, corticosteroids, etc.) except for a small control group. * generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning (only acute medication use as an exclusion so as to limit medication interaction but preserve possible chronic systemic inflammation interaction). * standard safety exclusionary criteria for mri such as metallic foreign bodies, pacemaker, etc., since the quantitative pet data analysis is based on anatomic criteria that are established uniquely for each subject by registration to his/her mri.
in-home cycling for individuals with pd: feasibility

Conditions: Parkinson Disease

Summary: this study will examine the influence of social support on exercise frequency, duration, quality of life, and overall activity level.

the benefits of exercise for individuals with parkinson disease (pd) have been well documented; however, individuals with pd living in rural and underserved urban settings are largely unable or unwilling to participate in group exercise programs due in large part to their distance from such programs and financial considerations. additionally, community based programs which provide social support and engagement have been shown to benefit elderly individuals as well as individuals with pathology, but are equally unattainable to this group. taking the exercise to these individuals via telemedicine or tele-exercise may be an ideal means of delivering this type of intervention. the long-term goal of this project is to improve outcomes for underserved populations of individuals with parkinson disease (pd) by providing access to in-home physical activity via a telehealth approach. approximately one million americans currently live with a diagnosis of pd and it has been estimated that delaying the progression by 20% would result in a $75,891 savings per individual based on reduced health care costs, income maintenance, increased duration of life and improved quality of life. however, individuals with pd of lower socioeconomic status, people of color and rural dwelling seniors have been critically underserved by clinical and academic programming resulting in poorer health outcomes. this study will examine the effects of social engagement during in-home exercise on a small sample of individuals with parkinson disease (pd). this pilot investigation will directly measure the effect of social support and engagement on exercise outcomes for rural dwelling individuals with pd.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic "definite pd" based upon established criteria * vision at or corrected to 20/40 or better * ability to independently ambulate for at least 10 minutes continuously * no reported vestibular or neurological disease (stroke or muscle disease) beyond their diagnosed pd * score of greater than or equal to 78 (no evidence of dementia) on the telephone adaptation of the modified mini-mental state exam * english speaking exclusion criteria: * contraindication for exercise * history of muscular or orthopedic diagnosis * inability to participate in the full duration of the study * currently exercising for 20 or more minutes per week

Keywords: social support exercise